Florence Borde

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High‐Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI‐PRODIGE Trial

S. Gill, J. Emile, J. Taïeb, 2019, Clinical colorectal cancer.

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

A. Fourrier-Réglat, F. Tubach, J. Prevost, 2019, British Journal of Cancer.